{"id":"NCT01008995","sponsor":"Centocor, Inc.","briefTitle":"A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Chinese Subjects With Moderate to Severe Plaque-type Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2011-07","completion":"2011-07","firstPosted":"2009-11-06","resultsPosted":"2012-09-14","lastUpdate":"2013-11-11"},"enrollment":322,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"ustekinumab","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"ustekinumab","otherNames":[]}],"arms":[{"label":"001","type":"EXPERIMENTAL"},{"label":"002","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy (good or bad effects) and safety of ustekinumab in the treatment of patients with moderate to severe psoriasis in China.","primaryOutcome":{"measure":"The Number of Patients Who Achieved at Least a 75% Improvement in PASI (Psoriasis Area and Severity Index) From Baseline at Week 12.","timeFrame":"Baseline (Week 0) to Week 12","effectByArm":[{"arm":"Placebo (CP)","deltaMin":18,"sd":null},{"arm":"Ustekinumab 45 mg (CP)","deltaMin":132,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":9,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":161},"commonTop":["Nasopharyngitis","Upper respiratory tract infection"]}}